Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Aldeyra Therapeutics, Inc.
< Previous
1
2
Next >
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
March 28, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
January 04, 2024
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
December 19, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
December 18, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
November 27, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap
November 01, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum
July 06, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa
June 29, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa
June 28, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic Cough
June 27, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic Cough
June 26, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE‑2 Trial in Allergic Conjunctivitis
June 14, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
June 02, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights
May 04, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis
April 13, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis
April 06, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough
March 30, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa
March 16, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
March 09, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma
March 02, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights
March 01, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease
February 28, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy
February 23, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease Trials
February 16, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
February 09, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease
February 07, 2023
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma
December 21, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial
December 13, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA
December 01, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Tickers
ALDX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.